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Abstract: Objective. To examine erythropoiesis in renal transplant preg-
nancies.
Methods. Retrospective cohort study of 30 renal transplant cases and
30 age, smoking and parity-matched healthy controls with normal in-
dex pregnancy. Retrospective chart review and assay of frozen antena-
tal serum (for serum erythropoietin concentration [serum EPO]),
transferrin receptor protein [TfR], ferritin, folate and B12) were per-
formed. The linear regression equation for normal pregnancy controls
was used to calculate predicted [serum EPO] and the observed:pre-
dicted (O:P) log [serum EPO] was plotted. The relationship between
[serum EPO] and haemoglobin (Hb) among transplant cases was con-
sidered to be different from that among controls if the slope of the
O:P log [serum EPO] versus Hb regression was significantly different
from zero.
Results. The transplant (14 cadaveric) to conception interval was (me-
dian [range]) 33.5 [4, 189] months. Immunosuppressants were azathio-
prine (n25), cyclosporine (n22) and:or prednisone (n25). Cases
were more often primiparous (20 vs. 7 [controls]; p0.01), had pre-ex-
istent hypertension (20 vs. 0 [controls]; pB0.001), developed new:in-
creased hypertension or pre-eclampsia (28 vs. 0 [controls]; pB0.001)
and an antenatal rise in creatinine (14 vs. 2 [controls]; pB0.001). In
early pregnancy, cases had similar EPO (15.2 [2.6, 84.6] vs. 15.7 [6.4,
41.0] [controls] U:L) but lower Hb (101 [65, 129] vs. 116 [106, 150]
g:L; pB0.001). Twenty-two (73%) cases had HbB100 g:L (vs. 4 [con-
trols]; pB0.0001); Hb was comparable at 6 wk postpartum. With ad-
vancing gestational age (GA), Hb remained stable and serum EPO
increased in both groups. The slope of the O:P log [serum EPO] versus
Hb for transplant cases was significantly different from zero within
both the 17–28 wk (slope9SEM: 0.01090.002; pB0.0001) and the
29–42 wk GA categories (0.00690.003; p0.02). Cases showed
smaller rises in serum TfR (change 481 [1471, 2780]) vs. 1119
[698, 4195] [controls] ng:mL; p0.005).
Conclusions. Anaemia frequently complicates renal transplant pregnan-
cies, in which serum EPO is inappropriately low and the rate of ery-
thropoiesis blunted.
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The World Health Organization defines anaemia in
pregnancy as a haemoglobin (Hb) concentration
less than 110 g:L (1), although many clinicians use
a cut-off of 100 g:L. Dilutional anaemia occurs in
normal pregnancy because plasma volume in-
creases to a greater degree than red blood cell mass
(2).
As in non-pregnancy, anaemia in pregnancy
may be caused by factors related to abnormal or
decreased production and:or increased destruction
1 Abstract presented at the International Society for the Study
of Hypertension in Pregnancy (ISSHP) Meeting, Kobe, Japan,
October, 1998.
2 YB is a Senior Research Associate of the National Fund for
Scientific Research (FNRS, Belgium).
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of red blood cells. The oxygen sensor in the kidney
controls production of erythropoietin (EPO), a gly-
coprotein growth factor that stimulates differentia-
tion of erythroid progenitor cells in the bone
marrow. There is an inverse relationship between
serum EPO and Hb concentrations (3); in the
presence of anaemia, EPO levels rise exponentially
in both non-pregnancy (4) and normal pregnancy
(5).
The John Radcliffe High Risk Obstetric Unit
manages all renal transplant pregnancies within the
Oxford Region. Progressive anaemia during preg-
nancy was observed in 3 women with stable crea-
tinine concentrations. However, in a
comprehensive literature review (6) of pregnancy
outcome following renal transplantation (based on
2409 women and 3382 pregnancies from 1961 to
1994), anaemia was not mentioned as a problem.
The objective of this retrospective study was to
examine, among gravidae with renal transplants,
the prevalence of anaemia and the appropriateness
of EPO production (as reflected by the relationship
between antenatal serum EPO and Hb). Compari-
sons were made with normal pregnancy controls,
all of whom were managed in the same High Risk
Obstetric Unit.
Methods
All women with pregnancies associated with renal
transplantation and followed by the High Risk
Obstetric Unit at the John Radcliffe Hospital, Ox-
ford, between 1986 and 1996, were identified by a
computerised search of the Unit database. ‘High
risk’ normal pregnancy controls, with a history of
either idiopathic recurrent miscarriage or foetal
loss or pre-eclampsia in previous pregnancies, were
also identified by a search of the same database.
Controls were selected based on the following
criteria: no history of a haematological disorder,
antenatal BPB140:90 mmHg, no antenatal
proteinuria or known renal disease, term delivery
and birthweight appropriate for gestational age
(GA). These ‘high risk’ normal pregnancy controls
were matched to transplant cases according to age
(94 yr), smoking (yes:no) and parity (91).
In order to examine the ‘normality’ of normal
pregnancy controls who had been referred to a
High Risk Obstetrics Unit, ‘general antenatal’
pregnancy controls were also sought (prospec-
tively) from general antenatal clinics at the same
institution. They were selected and matched to
cases according to the same criteria as for ‘high
risk’ normal pregnancy controls. Similar results
would justify use of ‘high risk’ normal pregnancy
controls who were recruited and managed in the
same way as cases.
For transplant cases and ‘high risk’ normal preg-
nancy controls, standardised forms were used to
collect the following background medical data by
retrospective hospital chart review: maternal de-
mographics (e.g. age, parity), history of renal dis-
ease, presence of pre-existent hypertension,
baseline (pre-pregnancy) creatinine, other medical
history, obstetrical history and immunosuppres-
sant and other drug therapy. For ‘general antena-
tal’ normal pregnancy controls, the same
information was collected by prospective chart
review.
Collection and freezing of serial antenatal and
postnatal serum have been routine in the Unit
since the mid-1980s. Routine collection periods
have been as follows: 517, 17–22, 23–28, 29–34
and 35–40 wk gestation, as well as both 2–5 days
and 6 wk postpartum. In addition to the GA at
which the frozen serum was taken, the following
laboratory results (corresponding to the same
serum sample) were abstracted from hospital
records: Hb (g:L) (as Hct was not available for
most patients), mean cell volume (MCV) of red
cells, platelet count (109:L), creatinine (mM),
uric acid (mM), dipstick proteinuria greater than
trace, mid-stream urine (MSU) culture result
(growth:no growth; organism if relevant) and 24-h
urinary protein (g). Blood film and reticulocyte
counts were not available. There was insufficient
information on creatinine clearance to be useful
and cyclosporine A (CsA) measurements could not
be used as they were not timed relative to ingestion
of the drug.
Serum samples that had been stored at 20°C
were allowed to defrost, for this first time, at room
temperature. All assays, except serum transferrin
receptor protein (TfR), were performed and the
samples were refrozen at 20°C and shipped to
Belgium where they were similarly defrosted, as-
sayed for TfR and refrozen. No samples were lost.
All samples were assayed for serum EPO, using a
chemiluminescence immunoassay (Nichols Insti-
tute Diagnostic Ltd., Essex, UK) with results ex-
pressed in U:L; the intra- and inter-assay
coefficients of variation (CV) were 5.5 and 6.7%,
respectively. Only the first and last antenatal serum
samples were assayed for ferritin, folate, vitamin
B12 and TfR. Soluble TfR are closely related to
the number of red blood cell precursors in the bone
marrow and provide a surrogate marker for the
rate of erythropoiesis, which is reliable in the ab-
sence of severe iron deficiency (which elevates TfR
values) (7); soluble TfR levels are particularly use-
ful for detection of multiple mechanisms of
anaemia as can exist among pregnant patients with
renal transplantation. Serum ferritin levels were
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assayed using a two-site incubation immunoradio-
metric assay (Bio-Rad Laboratories Ltd., Herts,
UK) expressed in mg:L; the intra- and inter-assay
CV were 4.2 and 11.1%, respectively. Serum folate
levels were determined using a modification of the
chloramphenicol-resistant Lactobacillus caseii
method (8) and expressed in mg:L; the intra- and
inter-assay CV were 4.0 and 11.5%, respectively.
Vitamin B12 was assayed using a non-boil ra-
dioimmunoassay kit (Ortho-Clinical Diagnostics,
Amersham, Buckinghamshire, UK), with the re-
sults expressed in ng:L; the intra- and inter-assay
CV were 4.9 and 13.1%, respectively. In accor-
dance with standard procedure, each assay in-
cluded both internal and external control samples.
TfR was assayed using an ELISA (9, 10) in which
each sample was run in duplicate; the intra- and
inter-assay CV were 4.3 and 8.1%, respectively.
The following outcomes were abstracted from
hospital records: pregnancy outcome (i.e. miscar-
riage, elective termination, intrauterine foetal
death, live birth, neonatal death), major malforma-
tions (defined as those having a major impact on
structure or function (11)), development of pre-
eclampsia (defined as BP]140:90 mmHg, ]0.3 g
of proteinuria by 24-h collection and:or oedema
(12)), new antenatal (isolated) hypertension (i.e.
BP]140:90 mmHg), worsening of pre-existent hy-
pertension (to ]140:90 mmHg) without protein-
uria, maternal pregnancy complications (e.g.
urinary tract infection, renal allograft rejection),
rise in antenatal and postnatal creatinine by 15%
(from the first antenatal sample, to a value \80
mM (13)), GA at delivery (wk), prematurity (i.e.
B37 wk gestation), birthweight (BW) (g), small for
gestational age (SGA) infants (i.e. B5th percen-
tile), method of delivery, neonatal health problems
(defined as those which prolonged hospital stay)
and long-term renal outcome (e.g. renal allograft
rejection or graft loss).
The primary outcome of interest was the rela-
tionship between serum EPO and Hb. However, a
two-way analysis of variance with repeated mea-
sures was first performed on one factor (GA) to
assess the relationship of serum EPO or Hb, with
both patient group and GA. Given that measure-
ments of EPO and Hb were made in time intervals
that were not equal for all women, an unequally
spaced repeated measurements design was used in
which the spatial power law modelled the time
series covariance structure of the repeated
measurements.
A detectable relationship between GA and either
serum EPO or Hb prompted examination of the
relationship between them within GA categories.
Within each GA category, the equation from the
linear regression of log [serum EPO] versus Hb (5)
among normal pregnancy controls was used to
calculate ‘predicted’ values of log [serum EPO]
from the Hb values of transplant cases. For trans-
plant cases, a linear regression was performed of
the observed over predicted (O:P) values of log
[serum EPO] versus Hb. A slope that was signifi-
cantly different from zero was taken to reflect a
different relationship between log [serum EPO] and
Hb than that seen among normal pregnancy con-
trols. pB0.05 was considered statistically signifi-
cant for all analyses. Analyses were performed
using SAS for IBM-compatible computers or
GraphPad Prism 2.01 (GraphPad Software, San
Diego, CA).
Of secondary interest were changes, from first to
last antenatal sample, in: i) platelets, as a marker
of the adequacy of other cell lines, ii) MCV, iii)
serum ferritin, iv) serum folate, v) serum B12, vi)
serum TfR and vii) serum creatinine. Obstetric
outcomes and maternal medical complications
were also compared between groups. Between-
group comparisons were made by Student’s t-test
or Mann–Whitney U-test (for continuous data)
and x2 or Fisher’s exact test (for categorical data).
Results
Baseline demographics
Twenty-four renal transplant cases, with 30 preg-
nancies, were identified and included in the study.
The indications for renal transplantation were
reflux nephropathy (n11, 1:11 nephrectomy of
native kidneys), vasculitis including systemic lupus
erythematosus (n5), chronic glomerulonephritis
(n4), familial nephrosis (n3), congenital mal-
formations (n2), focal segmental glomeruloscle-
rosis (n2), polycystic kidney disease (n1) and
unknown (n2). The transplant to conception
interval was (median [range]) 33.5 [4, 189] months.
Cadaveric (14 [47%]) and living related donor (15
[50%]) transplants were equally common; the na-
ture of one transplant was unknown. Only 6 (20%)
transplants had been followed by an episode of
acute rejection within the first 3 months post-oper-
atively. Immunosuppressants were most commonly
azathioprine, CsA and prednisone (n13), fol-
lowed in frequency by azathioprine and prednisone
(n7), CsA and prednisone (n5), azathioprine
and CsA (n4) and azathioprine alone (n1).
Thirty ‘high risk’ normal pregnancy controls,
with a history of either pre-eclampsia in a previous
pregnancy (n17) or unexplained recurrent mis-
carriage (n10), stillbirth (n2) or neonatal
death (n1) were identified. Their Hb, serum
EPO, platelet counts, serum ferritin, serum folate,
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serum B12 and TfR were found not to differ from
those of the 16 ‘general antenatal’ normal preg-
nancy controls (data not presented). Therefore,
only ‘high risk’ normal pregnancy controls were
compared with renal transplant cases for the re-
mainder of the analyses.
Table 1 shows that there were no differences
between renal transplant cases or ‘high risk’ nor-
mal pregnancy controls in terms of maternal age at
delivery, ethnicity, smoking or GA at booking.
Cases were more likely to be primiparous (whereas
controls were more likely to have had one previous
pregnancy) and have pre-existent hypertension.
Most (17:20) with hypertension had been treated
with antihypertensive medication before preg-
nancy, usually with a beta-blocker (13:17). One
case was on captopril, which was discontinued
when pregnancy was diagnosed. Cases also had
higher baseline serum creatinine and serum uric
acid and there was a trend toward higher 24-h
urinary protein. Three women had baseline serum
creatinine concentrations greater than 125 mM (i.e.
146, 167 and 185 mM).
Table 2 shows that at baseline, renal transplant
cases also had lower Hb concentrations than
normal pregnancy controls. The GA (mean9
SD) at which the first sample was stored was
not significantly different between transplant cases
and ‘high risk’ normal pregnancy controls. Cases
had higher MCV and serum ferritin, but simi-
lar serum folate, B12, EPO and TfR values.
Platelet counts did not differ between groups.
Equivalent numbers of transplant cases and nor-
mal pregnancy controls took iron supplements
during the pregnancy (i.e. 21:30 vs. 16:30 [con-
trols]; p0.18). No cases or controls reported
bleeding complications.
Erythropoiesis
Fig. 1 shows that from baseline throughout preg-
nancy, the Hb of renal transplant cases remained
significantly lower than that of ‘high risk’ normal
pregnancy controls (p0.0001). At some point in
gestation, Hb was less than 100 g:L among 22
(74%) transplant cases (vs. 4 [13%] [controls]) (pB
0.0001). There were few serum samples available
before 17 wk GA; therefore, postnatal Hb values
were examined as surrogates for antenatal values.
Postnatal Hb values were available for 20 of the 22
transplant cases with a antenatal Hb less than 100
g:L; only 1 had a Hb less than 100 g:L, compared
with no controls (p0.40). No cases or controls
were transfused postnatally.
Fig. 2 shows that among both transplant cases
and ‘high risk’ normal pregnancy controls, serum
EPO concentration increased with advancing GA
(p0.0003), but there was no difference between
groups (p0.75). In order to account for the GA
effect on serum EPO, the relationship between
serum EPO and Hb was examined within three GA
categories: B17, 17–28 and \29 wk gestation to
reflect early, mid- and late pregnancy.
Using data from ‘high risk’ normal pregnancy
controls, regression equations were obtained for
log [serum EPO] versus Hb for both the 17–28 wk
(2.95–[0.14Hb]; n46 samples) and 29–42 wk
categories (2.23–[0.07Hb]; n52 samples).
The analysis was not possible for early pregnancy
given the few available samples. Fig. 3a and b
shows that the O:P ratio of log [serum EPO] for
transplant cases differed significantly from zero,
for both the 17–28 wk (slope9SEM: 0.0109
0.002; r20.30; pB0.0001) and 29–42 wk
cateogories (0.00690.003; r20.08; p0.02).
This indicated a relationship between log [serum
Table 1. Baseline characteristics
Reference rangea Renal transplant pregnancies ‘High risk’ normal pregnancies pb
(n30) (n30)
Maternal age at EDD (yr) (mean9SD) n:a 26.795.0 28.795.0 0.12
Caucasian (%) n:a 29 (97) 30 (100) 0.31
20 (67)n:aPrimiparous (%) 7 (24)c 0.01
Nonsmokers (%) n:a 24 (80) 24 (80) 1.00
GA at booking (wk) (median [range]) n:a 10.5 [6, 34] 11.0 [5, 27] 0.74
Pre-existent hypertension (%) n:a 20 (67) 0 (0) B0.001
Serum creatinine (mM) (median [range]) 50–100 mM 100.5 [56.0, 185.0] 58.0 [43.0, 79.0] B0.0001
Serum uric acid (mM) (median [range]) 120–420 mM 337.0 [171.0, 609.0] 199.0 [122.0, 320.0] B0.0001
0.05224-h urinary protein (g) (median [range]) B0.3 g:24 hd 0.1 [0.1, 0.4] 0.1 [0.1, 0.2]
a Range for non-pregnancy unless otherwise stated.
b Values in bold are statistically significant at pB0.05.
c Data missing for one pregnancy.
d Normal range for pregnancy; lower limit of the assay is 100 mg per 24 h.
EDD (expected date of delivery), GA (gestational age).
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Table 2. Baseline laboratory data
Reference range for non-pregnancy Renal transplant pregnancies ‘High risk’ normal pregnancies pa
(n30) at 16.693.9 wk (n30) at 18.993.9 wk
\110 g:Lb 101 [65, 129] 116 [106, 150]Hb (g:L) (median [range]) 0.004
MCV (mM3) (median [range]) 76–100 mM3 93.3 [85.4, 107.6] 89.7 [80.9, 99.4] 0.005
150–450109:LPlatelet count (109:L) (median [range]) 258.0 [106, 345] 261.0 [151.0, 464.0] 0.79
14–200 mg:L 38.0 [10.0, 267.0]Serum ferritin (mg:L) (median [range]) 12.0 [4.0, 69.0] 0.004
Serum folate (mg:L) (median [range]) 2.1–28.0 mg:L 8.2 [4.4, 18.0] 8.1 [3.0, 18.0] 0.89
\150 ng:L 211.0 [76.0, 457.0] 204.0 [130.0, 472.0]Serum B12 (ng:L) (median [range]) 0.70
2–17.0 U:L 15.2 [2.6, 84.6]Serum erythropoietin (U:L) (median [range]) 15.7 [6.4, 41.0] 1.00
TfR (ng:ml) (median [range]) 2 900–7 100 ng:mL 3 439.0 [1 658.0, 5 912.0] 2 882.0 [1 581.0, 6 687.0] 0.12
a Values in bold are statistically significant at pB0.05.
b As per the World Health Organization.
Hb (haemoglobin), MCV (mean red cell volume), TfR (transferrin receptor protein).
EPO] and Hb that was different from that seen
among normal pregnancy controls, for both GA
categories.
One renal transplant case received two units of
packed red blood cells for a Hb of 59 g:L and 4 wk
later, went on to receive exogenous EPO with good
effect. Prior to EPO administration at 19 wk gesta-
tion, her serum EPO and Hb were 7.8 U:L and 60
g:L, respectively. After exogenous EPO adminis-
tration, her serum EPO and Hb peaked at 21.4
U:L and 92 g:L by 28 wk gestation. Her data were
not influential in the analyses. Administration of
EPO was not associated with poorly controlled
hypertension, although the patient did go on to
develop increasing hypertension and proteinuria
(maximum 0.98 g:d). She was induced at 36 wk
gestation and had a vaginal delivery of a infant
weighing 2724 g (50th percentile for GA). He had
Apgars of 3, 6 and 9 at 1, 5 and 10 min, respec-
tively and required intubation. There was no
neonatal polycythemia.
Only the change (from the first to last antenatal
samples) in TfR, platelets and creatinine differed
between groups; no differences were seen in the
change in serum ferritin, serum folate, serum B12
or MCV (data not presented). Cases showed a
smaller rise in TfR levels (median change [range] of
481 [1471, 2780] vs. 1119 [698, 4195] controls
U:L; p0.005), as well as larger rises in platelet
count (21 [96, 202] vs. 12 [102, 152] [con-
trols]109:L; p0.003) and creatinine concentra-
tion (12.38 [7.07, 6.19] vs. 1.77 [14.14, 30.94]
[controls] mM; p0.0002).
Pregnancy and maternal outcomes
Table 3 shows that pregnancy outcome was fa-
vourable for both groups. Among renal transplant
pregnancies, there were two intrauterine foetal
deaths (at 29 and 35 wk gestation); prematurity,
SGA infants and neonatal health problems (i.e.
special care baby unit admission due to prematu-
rity [n8] and sepsis [n1]) were also more fre-
quent. Prematurity among transplant pregnancies
was most commonly iatrogenic (n11) and most
commonly for pre-eclampsia (n7). Four women
with renal transplants had two or three pregnan-
cies, which did not appear to be more complicated
than the first.
Table 3 also shows that transplant cases suffered
an excess of medical complications such as preg-
nancy hypertension, urinary tract infections or
asymptomatic bacteruria, rise in antenatal serum
creatinine concentration and increasing protein-
uria. Twenty transplant cases developed new:wors-
ening hypertension; overall, 19 (63%) developed
hypertension and proteinuria that were thought to
be indicative of pre-eclampsia. Just over half of
renal transplant cases developed proteinuria, with
a peak (median [range]) value of 500 [200, 5900]
mg:24 h. Most transplant cases who developed
antenatal urinary tract infections or asymptomatic
bacteruria did so recurrently, i.e. on two (8 vs. 1
[control]), three (1 vs. 0 [control]), four (1 vs. 0
Fig. 1. Gestational age versus Hb (mean9SD) for renal trans-
plant cases (Tt) and normal pregnancy controls (NPC). Both




Fig. 2. Gestational age versus concentration of serum erythro-
poietin ([EPO]) (mean9SD) for renal transplant cases (Tt)
and normal pregnancy controls (NPC). Both antenatal as well
as postpartum day 3–5 and wk 6 are presented.
EPO, the latter would not change the relationship
between serum EPO and Hb (14) and her data
were not influential. The rate of erythropoiesis, as
reflected by serum TfR levels, was also blunted
among renal transplant cases given that TfR levels
failed to rise as much as those among normal
pregnancy controls, among whom this rise was
consistent with the erythropoiesis of normal
pregnancy.
Impaired erythropoiesis among women with re-
nal transplantation in pregnancy may result from a
number of factors. There was no evidence that
transplant cases were deficient in iron, folate or
vitamin B12. In fact, serum ferritin was actually
higher among transplant cases. Despite this, they
went on (inappropriately) to receive supplemental
iron in most cases. There was no global bone
marrow dysfunction, as indicated by similar
platelet counts at baseline and actually higher
platelet counts among transplant cases before de-
livery; this occurred despite a higher incidence of
proteinuric hypertension. A toxic effect of azathio-
prine therapy on erythropoiesis must be considered
(15). Most transplant cases (25 [83%]) were on
azathioprine and had higher MCV values through-
out pregnancy, consistent with azathioprine-in-
duced bone marrow toxicity. However,
azathioprine should not impair renal release of
EPO. CsA, which may decrease renal production
of EPO, was taken by 22:30 transplant cases (16).
Although renal transplant patients may be more
plasma volume expanded during pregnancy, ex-
plaining both lower Hb and EPO values, the rela-
tionship between the two should not have changed.
There was no evidence of haemolysis or excessive
blood loss to account for anaemia among trans-
plant cases.
Impaired renal function must be considered as
an aetiological factor in the demonstrated impaired
erythropoiesis among renal transplant cases. Sup-
port for the importance of renal graft function (17)
and inadequate production of EPO in the patho-
genesis of anaemia in renal transplant pregnancies
comes from the following data: i) a slightly ele-
vated but inappropriately low serum EPO in 1 such
patient (18), ii) a gradual increase in EPO concen-
tration during normal pregnancy (6), iii) higher
exogenous EPO requirements by some haemodial-
ysis patients during pregnancy (19) and iv) the
response of anaemic transplant patients to exoge-
nous EPO (5, 20). However, there are 3 reported
cases of transplant patients with stable creatinine
concentrations who required exogenous EPO dur-
ing pregnancy (17, 20). Some but not all of these
women were on azathioprine, which could con-
tribute to anaemia through bone marrow suppres-
sion.
[control]) or five occasions (2 vs. 0 [control]). An-
tibiotic prophylaxis was instituted in 1 case.
Of note, haematuria developed among most re-
nal transplant cases and more frequently than
among ‘high risk’ normal pregnancy controls; none
of the women had a concurrent urinary tract infec-
tion or identifiable renal stone disease and in no
instance were red or white blood cell casts iden-
tified. Graft loss occurred among 4 renal trans-
plant cases (13%), due to a failed transplant artery
repair (at 5 months postnatally) or rejection (n3;
at 6, 21 and 60 months postpartum).
Discussion
The history of renal transplantation and pregnancy
dates back 30 years. At present, about 1:50 women
of child-bearing age with a functioning renal allo-
graft become pregnant. These pregnancies are
recognised to be more complicated, both obstetri-
cally and medically (6). This single centre retro-
spective cohort of women, with predominantly
mild renal impairment and hypertension, experi-
enced rates of obstetric and medical complications
comparable to those described in the literature (6).
However, what was also demonstrated in this
study, and not previously shown, was the fact that
these pregnancies are also frequently complicated
by anaemia.
Hb values less than 100 g:L occurred among
most (74%) renal transplant pregnancies, but
among few (13%) normal pregnancy controls.
Postnatal anaemia was not a problem among ei-
ther transplant cases or controls. When assayed
between 17 and 42 wk gestation and compared
with normal pregnancy controls, transplant cases
were shown to have serum EPO levels that were
inappropriately low for concomitant Hb values;
although 1 transplant case received exogenous
132
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Not surprisingly, transplant cases in this study
were shown to have higher serum creatinine con-
centrations (at baseline and before delivery), 24-h
urinary protein excretion and a rise in antenatal
serum creatinine by more than 15%. However,
most cases had only a small rise in serum crea-
tinine during pregnancy, with only 3 having a
creatinine \200 mM prior to delivery. Anaemia is
not usually seen at the level of renal function seen
among transplant cases in this study.
The finding of unexplained haematuria, which
was confirmed by urine microscopy and seen
among both (the majority of) renal transplant
cases and (17% of) normal pregnancy controls, was
an unexpected finding and remains unexplained.
This was not associated with urinary tract infec-
tion, renal stone or evidence of rejection.
Although this study is the first to report on
erythropoiesis among renal transplant recipients
who become pregnant, it has many limitations. It
is retrospective in design. Many data were ab-
stracted from hospital records. Neither antenatal
nor early pregnancy Hb values were available, such
that postnatal values had to be used as surrogates.
Serum folate, not RBC folate, could be assayed.
Reticulocyte counts and Hct were not available
from the hospital charts. Most cases were taking
azathioprine, whereas many transplant patients to-
day are on non-azathioprine-containing drug
regimes. Most cases were also taking CsA, so it
was not possible to examine whether this medica-
tion had an impact on erythropoiesis independent
of renal function. Finally, we have no information
on other growth factors, such as interleukin-3,
which also regulate erythropoiesis and may be
altered by immunosuppressant therapy.
In summary, this retrospective cohort study
from a single tertiary care centre, demonstrates
that anaemia frequently complicates the pregnan-
cies of women with renal transplantation. Even in
Fig. 3. (a) O:P (observed over predicted) ratio of log {serum erythropoietin concentration [serum EPO]) versus Hb, for transplant
cases, for 17–28 wk gestation. Predicted values of log [serum EPO] for transplant cases were calculated from the regression of log
[serum EPO] versus Hb for normal pregnancy controls. The slope differs significantly from zero (pB0.0001). (b) O:P (observed over
predicted) ratio of log {serum erythropoietin concentration [serum EPO]) versus Hb, for transplant cases, for 29–42 weeks’
gestation. Predicted values of log [serum EPO] for transplant cases were calculated from the regression of log [serum EPO] versus
Hb for normal pregnancy controls. The slope differs significantly from zero (p0.02).
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Table 3. Pregnancy complications and outcome
Renal transplant pregnancies ‘High risk’ normal pregnancies pa
(n30)(n30)
Obstetric outcomes
Pregnancy outcome (%) live births 28 (93) 30 (100) 0.49
2 (7) 0.66Major malformations (%)b 3 (10)
B0.00139.0 [37.0, 41.0]36.0 [29.0, 39.0]Gestational age at delivery (wk) (median [range])
1 (3)17 (57) B0.001Prematurity (%)
Birthweight (g) (median [range]) 2 526 [550, 3 540] B0.0093 174 [2 660, 4 047]
0.050 (0)5 (17)SGA infants B5th percentile (%)
Method of delivery (%)
10 (33) 0.12Induction of labour (%) 17 (57)
Caesarean section (%) 12 (40) 9 (30) 0.59
Neonatal health problems (%) 9 (30) 1 (3) 0.01
Maternal outcomes
Pregnancy hypertensionc (%) 28 (93) 0 (0) B0.001
AN positive urine culture (%) 19 (63) 3 (10) B0.001
B0.0012 (7)14 (47)Rise in AN creatinine by 15%d (%)
Rise in PN creatinine by 15% (%) 1.016 (53) 17 (71)
16 (53) B0.0010 (0)24-h urinary protein \0.3 g (%)
5 (17)Haematuria (%) B0.00120 (67)
a Values in bold are statistically significant at pB0.05.
b Malformations among renal transplant cases were reflux nephropathy and hypospadias (n2) and among controls were bilateral hydrocoeles and
polydactyly of the foot.
c Defined as either pre-eclampsia or worsened pre-existent or new hypertension.
d Rise in creatinine was defined by a 15% increase, from the first antenatal measurement, to \80 mM.
AN (antenatal), PN (postnatal).
the absence of serious deterioration in renal func-
tion, the transplant kidney may be unable to in-
crease production of EPO and stimulate
erythropoiesis sufficiently to meet the increased
demands of pregnancy. If treatable causes of
anaemia have been ruled out, then consideration
should be given to treatment with exogenous EPO,
which does not cross the term placenta in 6itro
(21).
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